As highly activated SYK has been found to occur at a higher frequency in AML patients harboring the ITD mutant than patients expressing wt FLT3 [10], we were interested in exploring the activity of midostaurin against SYK using cell-based models of SYK-driven and SYK- and FLT3-driven leukemia. The gene discussed is SYK; the disease is acute myeloid leukemia.